PCV51 PROJECTED LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN 10/20MG) IN SPAIN

Nov 1, 2005, 00:00
10.1016/S1098-3015(10)67462-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)67462-1/fulltext
Title : PCV51 PROJECTED LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN 10/20MG) IN SPAIN
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67462-1&doi=10.1016/S1098-3015(10)67462-1
First page :
Section Title :
Open access? : No
Section Order : 28
Categories :
Tags :
Regions :
ViH Article Tags :